A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
- Registration Number
- NCT03435081
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 440
-
Have a diagnosis of atopic dermatitis (AD) at least 12 months before screening.
-
Have moderate to severe AD, including all of the following:
- EASI score ≥16
- IGA score of ≥3
- ≥10% of BSA involvement
-
Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.
-
Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).
-
Agree to use emollients daily.
-
Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
-
A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.
-
Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
-
Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
-
Have been treated with the following therapies:
- monoclonal antibody for less than 5 half-lives before randomization
- received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks before randomization
- received any parenteral corticosteroid administered by intramuscular or intravenous injection within 6 weeks of planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
- have had an intra-articular corticosteroid injection within 6 weeks of planned randomization
- probenecid at the time of randomization that cannot be discontinued for the duration of the study
-
Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
-
Have had major surgery within the past eight weeks or are planning major surgery during the study.
-
Have experienced any of the following within 12 weeks of screening: myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
-
Have a history of venous thromboembolic event (VTE), or are considered at high risk for VTE.
-
Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
-
Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
-
Have specific laboratory abnormalities.
-
Have received certain treatments that are contraindicated.
-
Pregnant or breastfeeding.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 milligram (mg) Baricitinib Placebo 2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind. 1 mg Baricitinib Baricitinib 1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind. 1 mg Baricitinib Placebo 1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind. Placebo Placebo Placebo administered orally every day. 2 milligram (mg) Baricitinib Baricitinib 2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitinib) Week 16 The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement Week 4 The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Percentage of Participants Achieving EASI75 (1 mg Baricitinib) Week 16 The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.
Percentage of Participants Achieving a 4-Point Improvement on the Itch Numeric Rating Scale (NRS) 16 Weeks The Itch NRS is a patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.
Percentage of Participants Achieving EASI90 Week 16 The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.
Percent Change From Baseline in EASI Score Baseline, Week 16 The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).
Least Squares (LS) Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.Change From Baseline in Skin Pain NRS Baseline, Week 16 Skin Pain NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours.
LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.Change From Baseline in Body Surface Area (BSA) Affected Baseline, Week 16 Body surface area affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs.
LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment Week 16 Percentage of participants developing skin infections requiring antibiotic treatment.
Percent Change From Baseline in Itch NRS Baseline, Week 16 The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.
LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA),and treatment-by-visit-interaction as fixed categorical effects and baseline, and baseline-by-visit-interaction as fixed continuous effects.Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM) Baseline, Week 16 The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life.
LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75) Week 16 The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score.
Percentage of Participants Achieving IGA of 0 Week 16 The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Percentage of Participants Achieving SCORAD90 Week 16 The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. SCORAD90 is defined as a ≥ 90% improvement from baseline in the SCORAD score.
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS) Baseline, Week 16 Atopic Dermatitis Sleep Scale (ADSS) is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep, frequency of waking, and difficulty getting back to sleep last night. Item 2, frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually.
LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.Percentage of of Participants Achieving EASI50 Week 16 The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI50 is defined as a ≥ 50% improvement from baseline in EASI score.
Change From Baseline in SCORAD Baseline, Week 16 The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.
LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit and treatment-by-visit interaction as fixed categorial effects and baseline and baseline-by-visit interaction as fixed continuous effects.Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score Baseline, Week 16 The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe."
LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.Change From Baseline on the Hospital Anxiety Depression Scale (HADS) Baseline, Week 16 The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.'
LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.Change From Baseline on the Dermatology Life Quality Index (DLQI) Baseline, Week 16 The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a little," "a lot," and "very much," with corresponding scores of 0, 1, 2, and 3, respectively, and unanswered or "not relevant" responses scored as "0." Scores range from 0 to 30 ("no impact on participant's life" to "extremely large effect on participant's life"), and a 4-point change from baseline is considered as the minimal clinically important difference threshold.
LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA),visit, and treatment-by-visit-interaction as fixed categorical and baseline, and baseline-by-visit-interaction as fixed continuous effects.Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire Baseline, Week 16 The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment.
LS Mean were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Index Score United States (US) and United Kingdom (UK) Algorithm Baseline, Week 16 The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the UK algorithm, with scores ranging from -0.594 to 1, and the US algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state.
LS Means were calculated using a MMRM model with treatment, baseline disease activity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS) Baseline, Week 16 EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranges from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
LS Means were calculated using a MMRM model with treatment, baseline disease activity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.
Trial Locations
- Locations (81)
Care Access Research-Walnut Creek
🇺🇸Walnut Creek, California, United States
GWU/Medical Faculty Associates
🇺🇸Washington, District of Columbia, United States
Hamzavi Dermatology
🇺🇸Fort Gratiot, Michigan, United States
California Dermatology and Clinical Research Institute
🇺🇸Encinitas, California, United States
The Indiana Clinical Trials Center, PC
🇺🇸Plainfield, Indiana, United States
Wallace Medical Group, Inc.
🇺🇸Beverly Hills, California, United States
Advanced Medical Research
🇺🇸Sandy Springs, Georgia, United States
University Dermatology
🇺🇸Darien, Illinois, United States
Dermatologists of Southwest Ohio, Inc.
🇺🇸Mason, Ohio, United States
Dermatology & Laser Center of Charleston
🇺🇸Charleston, South Carolina, United States
Virginia Clinical Research
🇺🇸Norfolk, Virginia, United States
Institute for Skin Advancement
🇨🇦Calgary, Alberta, Canada
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Austin Institute for Clinical Research, Inc.
🇺🇸Pflugerville, Texas, United States
Office of Dr. Samuel Sanchez PSC
🇵🇷Caguas, Puerto Rico
Ponce School of Medicine CAIMED Center
🇵🇷Ponce, Puerto Rico
Allergy Research Canada Inc.
🇨🇦Niagara Falls, Ontario, Canada
Office of Dr. Alma M. Cruz
🇵🇷Carolina, Puerto Rico
Simcoderm Medical & Surgical Dermatology Centre
🇨🇦Barrie, Ontario, Canada
SKiN Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
Innovaderm Research Inc
🇨🇦Montreal, Quebec, Canada
Johnson Dermatology
🇺🇸Fort Smith, Arkansas, United States
Tien Q. Nguyen, MD inc. DBA First OC Dermatology
🇺🇸Fountain Valley, California, United States
Keck School of Medicine University of Southern California
🇺🇸Los Angeles, California, United States
Southern California Dermatology
🇺🇸Santa Ana, California, United States
Clinical Science Institute
🇺🇸Santa Monica, California, United States
Clinical Research Center of CT/NY
🇺🇸Danbury, Connecticut, United States
Univ of Connecticut
🇺🇸Farmington, Connecticut, United States
Treasure Valley Dermatology
🇺🇸Boise, Idaho, United States
Meridian Clinical Research
🇺🇸Savannah, Georgia, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
The South Bend Clinic
🇺🇸South Bend, Indiana, United States
Modern Research Associates PLLC
🇺🇸Dallas, Texas, United States
Acclaim Dermatology, PLLC
🇺🇸Sugar Land, Texas, United States
Lynderm Research Inc
🇨🇦Markham, Ontario, Canada
Tufts Medical Center
🇺🇸Boston, Massachusetts, United States
Dermatology and Skin Cancer Specialists
🇺🇸Rockville, Maryland, United States
Miami Dermatology & Laser Research
🇺🇸Miami, Florida, United States
Dawes Fretzin Clinical Research
🇺🇸Indianapolis, Indiana, United States
Medical Center for Clinical Research
🇺🇸San Diego, California, United States
University Clinical Trials, Inc.
🇺🇸San Diego, California, United States
Texas Dermatology and Laser Specialists
🇺🇸San Antonio, Texas, United States
Dr. Chih-ho Hong Medical Inc.
🇨🇦Surrey, British Columbia, Canada
Centre de Recherche Dermatologique de Quebec Metropolitain
🇨🇦Quebec, Canada
Riverchase Dermatology and Cosmetic Surgery
🇺🇸Pembroke Pines, Florida, United States
Olympian Clinical Research
🇺🇸Largo, Florida, United States
Arlington Dermatology
🇺🇸Rolling Meadows, Illinois, United States
York Dermatology Center
🇨🇦Richmond Hill, Canada
Brigham and Womens Hospital
🇺🇸Boston, Massachusetts, United States
Medicor Research Inc
🇨🇦Sudbury, Ontario, Canada
XLR8 Medical Research
🇨🇦Windsor, Ontario, Canada
Solutions Through Advanced Research, Inc.
🇺🇸Jacksonville, Florida, United States
Center for Dermatology Clinical Research, Inc.
🇺🇸Fremont, California, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Dermatologic Surgery Specialists, PC
🇺🇸Macon, Georgia, United States
Great Lakes Research Group, Inc.
🇺🇸Bay City, Michigan, United States
Central Dermatology PC
🇺🇸Saint Louis, Missouri, United States
Wright State Univ School of Medicine
🇺🇸Fairborn, Ohio, United States
DermResearchCenter of New York, Inc
🇺🇸Stony Brook, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Bexley Dermatology Research
🇺🇸Bexley, Ohio, United States
Dermatology and Skin Surgery Center
🇺🇸Exton, Pennsylvania, United States
Kirk Barber Research
🇨🇦Calgary, Alberta, Canada
Bellaire Dermatology
🇺🇸Bellaire, Texas, United States
University of Utah MidValley Dematology
🇺🇸Murray, Utah, United States
Kingsway Clinical Research
🇨🇦Etobicoke, Ontario, Canada
The Centre for Dermatology
🇨🇦Richmond Hill, Ontario, Canada
GCM Medical Group PSC
🇵🇷San Juan, Puerto Rico
Stratica Medical
🇨🇦Edmonton, Alberta, Canada
Multicare Health System
🇺🇸Tacoma, Washington, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
University of California Davis-Dermatology
🇺🇸Sacramento, California, United States
Oregon Dermatology and Research Center
🇺🇸Portland, Oregon, United States
University of South Florida
🇺🇸Tampa, Florida, United States
ForCare Clinical Research
🇺🇸Tampa, Florida, United States
OHSU Center for Health and Healing
🇺🇸Portland, Oregon, United States
Dermatology Specialist
🇺🇸Louisville, Kentucky, United States
Skin Specialists, P.C
🇺🇸Omaha, Nebraska, United States
K. Papp Clinical Research Inc
🇨🇦Waterloo, Ontario, Canada
Clinical Partners LLC
🇺🇸Johnston, Rhode Island, United States
Enverus Medical Research
🇨🇦Surrey, British Columbia, Canada